Lung cancer remains the leading cause of cancer incidence and mortality worldwide. Approximately 60% of the world's new cases of lung cancer and deaths from it are expected in Asia in 2018. Currently, lung cancer screening using low-dose computed tomography (LDCT) is recommended for heavy smokers in North America, Europe and some countries in Asia. Tobacco smoking being the major risk factor for lung cancer, but in Asia, lung cancer in never-smokers (LCINS) is also a concern. This paper reviews on lung cancer incidence, mortality, etiology, smoking in Asia, and systematic reviews on LDCT lung cancer screening studies, including ongoing projects and recommendation on lung cancer screening in Asia. Some of the earliest studies of LDCT lung cancer screening worldwide were in Asia. Many countries in Asia have developed LDCT screening studies in various high-risk participants. Currently, there are several ongoing large-scale lung cancer screening trials to evaluate the efficacy of LDCT screening for never-smokers and light smokers, as well as heavy smokers, and to evaluate the feasibility of population-based LDCT lung cancer screening. and compare Asian guidelines for LDCT screening and lung nodule management in each country and provide the timeline of LDCT lung cancer screening studies and guidelines in Japan, China, Korea, and Israel. We provide the information by different regions of Asia,
Introduction
Lung cancer remains the leading cause of cancer incidence and mortality worldwide and these are increasing. 1, 2 So that approximately 60% of the world's new lung cancer cases and death predicted occur in Asia in 2018, and over one-third of these will occur in China. 3 Meanwhile, the lung cancer incidence of both sexes in the US and men in European countries has been decreasing over the past two decades. 2, 4, 5 In China, the trend remains stable for men but is increasing in women between 2000 and 2011 6 , and since the beginning of this century, lung cancer has the highest incidence and mortality of all types of cancer. [7] [8] [9] Lung cancer screening using LDCT has been studied since the 1990s. Some of the earliest studies of LDCT screening for lung cancer were performed in Japan. 10, 11 Currently, LDCT has been recommended for lung cancer screening among heavy smokers in North America, Europe, and some countries in Asia. [12] [13] [14] [15] [16] [17] [18] [19] [20] There are regional and racial/ethnic differences in lung cancer which impact the cancer susceptibility, incidence, and mortality. Moreover, the cost of LDCT screening and insurance coverage are also the important factors in lung cancer screening and mortality.
In this article, we initially compare lung cancer incidence, mortality, and current smoking in individual countries in Asia. Then, we review and summarize the published LDCT lung cancer screening trials including observational studies, randomized controlled trials, and other ongoing projects in Asia. Finally, we review
Incidence and mortality rate of lung cancer in Asia
Lung cancer remains the leading cause of cancer incidence and mortality worldwide and is increasing, from 1.8 million new lung cancer cases and 1.6 million related deaths in 2012 to 2.1 million new cases (11.6%) and 1.8 million deaths in 2018 estimated by GLOBOCAN 2018. 1, 2 Most of the world's new lung cancer cases (1.2 million, 58.5%) and lung cancer deaths (1.1 million, 60.7%) occur in Asia and over one-third of these occur in China with 774,323 and 690,567 cases, respectively. 3 From recent data on global cancer statistics 2018, the highest age-standardized incidence rate per 100,000 population among Asian males are seen in Eastern Asia (47.2%), followed by Western Asia (38.8%), South-Eastern Asia (26.3%), and South-Central Asia (9.4%). 2, 3 Men in Turkey had the highest incidence rates (70.6), followed by Armenia (58.5%), North Korea (48.2%), and China (47.8%) ( Table 1) . 3 The highest lung cancer incidence rates among Asian women are seen in Eastern Asia (21.9), South-Eastern Asia (9.6%), Western Asia (7.8%), and South-Central Asia (3.4%), respectively. 2, 3 Women in North Korea had the highest incidence rates (27.4) , followed by Brunei (26.6%), China (22.8%), South Korea, and Singapore (17.2%). 3 The mortality-to-incidence ratio ranged from 0.87 to 0.97 in men and from 0.78 to 0.94 in women. Lung cancer patients in Eastern Asia had the lowest ratio, particularly women (0.87, and 0.78 in men and women, respectively), followed by South-Eastern Asia (0.90, 0.88), South-Central Asia 0.94, 0.94), and highest in Western Asia (0.97 and 0.94).
Etiology

Tobacco smoking
Tobacco smoking is a major risk factor for lung cancer, particularly in men, and causes nearly 80% of male and 50% of female lung cancer deaths. China is the largest tobacco producer and consumer in the world with over 2.9 million tons of tobacco manufactured in 2016. 12, 13 According to the 2010 Global Adult Tobacco Survey, there were an estimated 301 million Chinese current smokers, aged 15 years, and older, nearly one-third of the world's total 21, 22 with the prevalence of smoking was 52.9% among men and 2.4% among women. 14, 15 Although the percentage of smoking is decreasing to 48.4% and 2.0%, respectively, the rate remains high. 23, 24 In the United States, the percentage is 24.6% among men and 19.1% among women. 24 From World Health Statistics on age-standardized prevalence of current tobacco smoking among persons aged 15 years and older in 2016. 24 Among Asian men, Timor-Leste has the highest rate (78.1%), follow by Indonesia (76.1%), Georgia (55.5%) and Maldives (55%). Among Asian women, the highest smoking prevalence rate was observed in Lebanon (26.9%), Israel (15.4%), Turkey (14.1%) and Japan (11.2%) ( Table 1) .
It is of note that the lung cancer incidence and smoking rates in Asian women are lower compared to women in Western countries with the similar lung cancer incidence rate, particularly in Brunei and China. In Brunei and China, women had lung cancer incidence rates of 26.6 and 22.8 per 100,000, respectively, with smoking prevalence of 2% and 1.9%, respectively. The corresponding rates for women in Poland and France were 24.5 and 22.5 with smoking rates of 23.3% and 30.1%, respectively). 2, 3, 24 
Nontobacco factors
It is estimated that 25% of the lung cancer patients are never-smokers. There are major clinical differences based on ethnicity, gender, and histology in lung cancer in neversmokers (LCINS), particularly in Asian women, which target the distal airways and flavor adenocarcinoma histology. It has been estimated that 15% of men and 53% of 
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women with lung cancer worldwide are never-smokers. 25 The proportion of lung cancers in women never-smokers is particularly high in women in Eastern (61%) and Southern Asia (83%), but in the United States, only 15% of all lung cancer found in women never-smokers. 26 Environmental risk factors are reported to play a predominant role in LCINS, including second-hand smoke (SHS) exposure, environmental particulate matter, occupational exposures, indoor air pollution, and radon. It was estimated that more than half of the lung cancer deaths are attributable to ambient fine particles in China. 7 These risk factors appear to be responsible for a significant proportion of lung cancer in Chinese never-smokers, but account for a smaller proportion of cases in Europe and North America. The combined population attributable fraction (PAF) for SHS exposure occurring at home and in the workplace was highest in Chinese women (24.11%), coal smoke (19.93%), and tuberculosis (12.67%). While the PAF for SHS was only 5.63%, and tuberculosis infection was 1.14% among North American women. 27 Genetic factors also play an important role in lung cancer etiology of LCINS. There are differences in genetics and molecular changes between LCINS and lung cancer in smokers. Smoking-related cancers are associated with KRAS mutations, STK11, SMARCA4, and high numbers of other mutations, especially C:G>A:T transversions, while cancers in never-smokers are associated with EGFR mutations, ALK translocations, PTEN, PIK3CA, and low numbers of mutations targeting C: G>T:A transitions. 26, 28, 29 The overall frequency of EGFR mutations in patients with NSCLC of adenocarcinoma histology in Asia was higher than in Europe (15%) and North America (22%). However, the EGFR rates vary in Asia, from being as high as 47% in Eastern and South-Eastern Asia) with the highest occurring rate of 64% in Vietnam, and lower rates of 26% in Indian subcontinent and 23% in Bangladesh. 30 Moreover, a lower prevalence of KRAS mutations, which is associated with poorer prognosis in lung cancer patients with NSCLCs, is observed in Asians (3.8-8%) than in Caucasians (18-26%). [31] [32] [33] There are more than 150 Genome-wide association studies (GWAS) that have been published in lung cancer. In 2008, three studies identified three potential susceptibility loci for lung cancer. 34, 35 Chromosomes 15q25 and 5p15.33, containing the telomerase reverse transcriptase (TERT) gene that have been confirmed, but the cancerassociated role of the locus on 6p21-6p22 remained more controversial. 26, 35 A multistage GWAS of lung cancers in never-smoking Asian women in six Asian countries (mainland China, South Korea, Japan, Singapore, Taiwan, and Hong Kong) identified associated loci; TERT at 5p15.33, TP63 at 3q28, VTI1A on chromosome 10 and ROS1-DCBLD1. Moreover, this study showed no evidence of association for lung cancer at 15q25, which the authors mentioned provided "strong evidence that this locus is not associated with lung cancer independent of smoking. 36 LDCT screening for lung cancer in Asia Japan Japan initiated LDCT screening for lung cancer study in 1993 in one of the earliest studies of LDCT lung cancer screening worldwide and developed the mass screening with mobile CT in 1996. 10, 11, 3740 As of 2009, the LDCT screening had spread throughout Japan, as 127,897 screenings in 61 institutions were performed. There are guidelines for Japanese LDCT lung cancer screening and management of pulmonary nodules detected by LDCT and also standardization of LDCT screening programs and certification of physicians and radiologic technologists.
In 1993, the Anti-Lung Cancer Association (ALCA), a for-profit organization to screen dues-paying participants for lung cancer, introduced LDCT at the initiative of the National Cancer Center Study Group as a screening modality. 11, 38, 41 The ALCA screening project using LDCT, chest x-ray (CXR), and 3-day pooled sputum cytology with a 6-month interval in smokers aged 38, 44, 46 reported a LDCT screening program during 1998-2006 in 25,385 screened individuals aged ≥50 years in Hitachi city. The baseline and overall lung cancer detected rate was 0.67% and 0.34%, respectively, with 91% and 85% stage I lung cancer, respectively. The 5-year survival rate was 90%. Comparison of all causes of death among patients with lung cancer detected on LDCT screening, current and former smokers (HR=4.7) had a poorer prognosis than never-smokers. When comparing on nodule consistency, patients with cancer in a solid nodule (HR=4.6) had a poorer prognosis than those with cancer in a nonsolid or part-solid nodules. The lung cancer mortality rate of Japanese aged 50-79 decreased by 24% in 2005-2009 compared with the national statistics during 1995-2004. The author suggested that a wide implementation of LDCT screening may decrease lung cancer in community 4-8 years after the introduction of the screening. 44 The Japanese Society of CT Screening (JSCTS) was founded in 1994 as "The Society of Thoracic CT Screening". 38 The society has organized annual seminars to spread knowledge and improve skills of LDCT screening, produced and published "Manual for single-detector CT (SDCT) and MDCT imaging methods" in 2004, and revision in 2005, 47 "guidelines for the management of pulmonary nodules detected by low-dose CT" for 3 versions, in 2005, 2009, and 2013, respectively, 48 and preparing software for education (ALCA Project: The Simulation). In 2013, the LDCT screening for lung cancer recommendation was published in "Japanese Imaging Guidelines" by the Japan Radiological Society and the Japanese College of Radiology. 19 (Details are in current guidelines in Asia section.)
LDCT screening for lung cancer had spread widely in Japan, the JSCTS performed a nationwide survey of LDCT screening among member institutions and reported 34,181 screened participants in 20 institutions in 2000 had increased to 127,897 participants in 61 institutes in 2009 with the lung cancer detection rate of 0.33% and 0.15%, and 78.8% and 67.7%, of stage 1 lung cancer, respectively. 38, 49 To standardize LDCT screening, the Accreditation Council for Lung Cancer CT Screening was founded by a joint committee in April 2009. 38, 50 Physicians are certified on the basis of specialist qualifications and the completion of specified courses, and technologists are certified on the basis of the completion of specified courses and tests; the certifications are to be renewed every 5 years. As of 2015, there are 1347 certified physicians and 854 certified technologists. 38, 47 After many observational screening trials of asymptomatic adults in Japan, Sagawa et al 51, 52 started the JECS Study (The Japanese randomized trial for evaluating the Efficacy of low-dose thoracic CT Screening for lung cancer in non-smokers and smokers under 30 pack-years), a 10-year RCT compared LDCT once every 5 years with CXR in people aged 50-70 with a smoking history <30 pack-years, in 2010 ( Figure 1 ). This study was supported by the Ministry of Health, Labour and Welfare, and the Japan Agency for Medical Research and Development. A sample size of 13,500 subjects for each arm was required to detect a 60% mortality reduction after 10 years. As of April 1, 2018, over 7500 participants have registered for the JECS Study. 50 
China
The LDCT screening for lung cancer in China initiated in 1994. 53 International collaborative programs were established in 2003 with I-ELCAP and later with US National Cancer Institute and with NELSON in Europe. 53, 57 LDCT screening was supported by the Chinese Central Government Public Health Special Subsidy in 2009. Large-scale screening programs have been developed with aims to evaluate the feasibility of conducting population-based LDCT lung cancer screening 57, 58 and determining the lung cancer-specific mortality benefit and effectiveness of LDCT screening with/without biomarkers in various high-risk participants. 59 LDCT screening for lung cancer was initiated in 1994 at the 5th Affiliated Hospital of Sun Yat-Sen University in Zhuhai. In 2003, its collaboration with the I-ELCAP started. 53 Prior to the collaboration with I-ELCAP, a single slice spiral CT was used for screening and CT interpretation was based on morphology and interval growth, and with 0.55% detection rate of lung cancer and 76.9% stage I NSCLC, and showed that the lung cancer detection rate of female SHS was higher than in high-risk smokers and male SHS (1.4% vs 0.9%, 0.4%). 8, 54 Up to 2018, a total of 41,300 participants were enrolled with lung cancer detection rate of 0.4%. 59 In 2009, LDCT lung cancer screening was included in the cancer early detection and treatment program supported by the Chinese Central Government Public Health Special Subsidy. A national demonstration program, Rural China Screening Programme (RuraCSP), was initiated to evaluate the feasibility of conducting population-based LDCT lung cancer screening in the Chinese setting. 57, 58, 61 This program was a prospective multi-center observational study of annual LDCT screening among the high-risk population with different inclusion criteria at the different regions and centers. For example, tobacco smoking was the criteria at the Dagang Oilfield center, while indoor air pollution exposure was the criteria at the Xuanwei center.-57 Up to July 2017, a total of 13,000 participants had. The lung cancer detection rate was 1% (0.3-2.9%) and 40% (25-73%) of early-stage lung cancers were identified in baseline round. For annual screening, the lung cancer detection rate was 0.4% (0.1-0.8%) and 56% (46-90%) were early-stage lung cancers. The highest prevalence (2.9%) and incidence (0.8%) were observed in Xuanwei center. 58 In 2012, the Chinese government launched Cancer Screening Program in Urban China (CanSPUC), a 5-year annual LDCT screening for lung cancer in urban residents with high-risk criteria that is regional-dependent. This study aimed to promote the early detection and treatment of the five top cancers (lung, breast, colorectal, liver, and upper digestive tract cancers) in urban areas of China. 8, 58, 61, 62 Up to 2018, 20 provinces/municipalities have been included. 61 The RuraCSP and CanSPUC programs involved other aspects including health promotion, technical training for doctors and technical personnel, smoking cessation, biomarker discovery, and validation. To sustain the development of a national screening program, the two programs have been included into the special program of medical insurance system reform in China to explore the possibility of incorporating LDCT lung cancer screening in the routine health insurance system in China. 58 Following the national programs, several regional, national, and international programs have been initiated. During 2013-14, there were 2 major programs of science & technology commission on lung cancer screening project initiated in Shanghai (2013) 63 and Beijing Municipality (2014), and a National Health Public Welfare Scientific Research Project to study the application of Biomarkers in Screening for Five Common Cancers (2014). 59 In 2014, the CICAMS also collaborated with US NCI and initiated the China Cancer Screening Trial Feasibility Study, a multicenter RCT in 3 cities, funded by the CICAMS, and the National Health and Family Plan Committee of China 56, 61, 64 to obtain information necessary to design a long-term RCT on lung and colorectal cancer screening, and to test colorectal cancer screening strategies in China. The study protocol is illustrated in Figure 2 . As of March 2015, a total of 2696 participants were enrolled. There were 6.5% and 6.1% of participants who had baseline LDCT findings suspicious for lung cancer in arm 1 and arm 2, respectively. The positive colorectal cancer screening was 34.1% with colonoscopy screening, 8.0% with OC-FIT test, 4.5% with InsureFIT test, and 5.8% with Septin9 test. In addition, the CICAMS had a collaboration project with the MD Anderson Cancer on Lung Cancer Early Detection. 59 In 2015, based on the protocol of LDCT lung cancer screening program in rural China, a China national lung cancer screening guideline was developed by lung cancer early detection and treatment expert group appointed by the National Health and Family Planning Commission and it was revised in 2018. 18, 58, 65 The detail is in current guidelines in the Asia section.
In 2016, a collaborative project, Netherlands-China Big-3 screening, 55 a multicenter study, was started to improve the early detection of 3 important diseases: lung cancer, COPD, and cardiovascular diseases, by using the newest ultra-LDCT techniques and identifying the biomarkers of the diseases at a very early stage. The result will 56, 64 In 2017, the National Key R&D Program of China launched the China National Cancer Early Screening (CHANCES) Trial: Lung and Colorectal Cancer, a multicenter nationwide RCT on 78,500 high-risk smokers and never-smokers (1) to perform the largest prospective RCT on lung cancer screening in China, (2) to evaluate the effectiveness of different screening frequency (no screening, 3 annual LDCTs and 2 biannual LDCTs), (3) to evaluate the effectiveness of LDCT with/without biomarkers, and (4) to determine whether screening with LDCT could reduce mortality from lung cancer in China. The study protocol is illustrated in Figure 3 . The project also established data management system with several main functions as web-based data management platform, automated risk assessment, structured reporting, and management, automatically generating to-do list, and autonotification. 59 Taiwan Lung cancer screening studies, initiated in 2007, were first reported in Taiwan in 2012. Most of them demonstrated a high baseline incidence in non-NLST eligible criteria, particularly in women and individual with a family history of lung cancer in Taiwan. 66, 67 Currently, there is ongoing a National Lung Screening Program aimed to perform LDCT screening for lung cancer in never-smokers and validate the risk single-nucleotide polymorphisms (SNPs) previously identified that associated with susceptibility to lung cancer in never-smokers.
In 2007, Wang et al 68 started a 3-annual LDCT screening in lung cancer families with the following criteria: (1) first-degree relatives had lung cancer (simplex family) or ≥2 relatives with lung cancer (multiplex family), and (2) age≥55 years. A total of 1125 participants from 559 families of lung cancer, 810 patients from 418 simplex families and 315 came from 141 multiplex families, were recruited between August 2007 and November 2009. The baseline lung cancer detection was 1.7% with 63% stage I. This study demonstrates evidence of lung cancer prevalence based on family risk.
Chen et al 67 reported a retrospective study of LDCT screening in the setting of annual medical examinations in one hospital in 3339 individuals aged ≥18 years and no prior history of any cancer during January-December 2012. The overall cancer detection rate was 1.02% with 99% of stage 1 carcinoma. A very high detection rate (6.2%) in subgroup aged younger than 50 years with a positive family history of all types of cancers in firstdegree relatives was demonstrated. Wu et al 66 showed retrospective data of 1763 asymptomatic healthy subjects aged 40-80 years who underwent LDCT during 2013-2014. The lung cancer detection rate in NLST eligible participants vs noneligible female and male participants were 0.7% vs 2.6% and 0.6%, respectively. The data showed that female sex (OR 6.367; P=0.003) and a family history of lung cancer (OR 3.017; P=0.016) were significant predictors of lung cancer in Taiwan. From this cohort with 2 months of extension period, Hsu et al 69 analyzed the diagnostic accuracy of modification of the ACR Lung Imaging Reporting and Data System (LungRADS), from data of 1978 screened participants with 32 pathological proven adenocarcinoma (3AAH, 3 AIS, and 20 invasive adenocarcinoma). The data show using modified Lung-RADS category 2C (GGN: <20 mm) as cutoff, had the higher area under the curve (AUC) of 0.973 in predicting adenocarcinoma spectrum lesions (sensitivity of 100%, specificity of 89.3%), significantly higher than of LungRADS (0.815, P<0.001) and NLST criteria (0.906, P<0.001). Moreover, using category 3B (Part solid: ≥6 mm with solid component <6 mm) as cutoff had an AUC of 0.992 in predicting invasive adenocarcinoma (sensitivity of 95%, specificity of 97.8%). The author concluded that the modified Lung-RADS may substantially improve sensitivity while maintaining specificity for detection of adenocarcinoma spectrum lesions in an Asian population.
In 2014, Taiwan developed a National Lung Screening Program, Taiwan Lung Cancer Screening for Never-smoker Trial (TALENT), sponsored by the Ministry of Health and Welfare. This prospective, nationwide, multicenter study, aimed to perform LDCT screening for lung cancer in never-smokers and validate the risk SNPs previously identified that associated with susceptibility to lung cancer in never-smokers. 70, 71 LDCT were performed annually for three consecutive years in participants aged between 55 and 75 years, never-smoker with one of the following risk: (i) family history of lung cancer within third-degree relatives, (ii) passive smoke exposure, (iii) history of pulmonary TB or COPD, (iv) cooking index ≥110, or (v) not using ventilator during cooking. SNP typing was studied in every enrolled subject and integrated into a risk score prediction model. Up to May 13, 2018, a total of 10,397 subjects were enrolled, approximately 75% were women and had environmental smoking exposure. The lung cancer detection rate was 2.34% with 95.1% stage I. Four SNPs (TERT, TP63, HLA-DRB9/HLA-DRB5, HLA-DRB1/ HLA-DQA1) significantly associated with the risk of lung cancer. The lung cancer cases had the risk score point significantly higher than normal (59.4±28.23 vs 50.1±28.84, p<0.0001).
South Korea
LDCT lung cancer screening has been studied in Korea since 1999 and the Korean guideline for lung cancer screening was launched in 2015. Currently, there is a Korean-Lung Cancer Screening Project (K-LUCAS), a pilot project to assess the effectiveness and feasibility of lung cancer screening to implement national cancer screening program in Korea.
Chong et al 72 reported a LDCT screening in 6406 asymptomatic Korean participants aged ≥45 years during 1999-2003 at Samsung Medical Center. Of the 6406, 52% were high-risk (≥20 pack-years) ever-smokers, 25% were non-high-risk ever-smokers, and 23% were never-smokers. The overall proportion of total lung cancer cases over the number of baseline participants was 0.36% with 62% being stage 1.
Yi C.A. et al 73 evaluated the performance of LDCT screening comparing with CXR for lung cancer detection in 12,427 asymptomatic Korean participants with diverse risks for lung cancer in a nontrial setting during 2006-2008. In the non-high-risk group, LDCT had a higher lung cancer detection rate (adjusted OR, 5.07) and survival than of CXR group (adjusted HR, 0.08). Meanwhile, no difference in detection or survival of lung cancer was observed in the high-risk group. Lung cancers in the non-high-risk group were predominantly adenocarcinomas (96%), and more likely to be part-solid or nonsolid compared with those in the high-risk group (p=0.023).
In 2015, the Korean guideline for lung cancer screening was launched by a Korean multi-society collaborative committee. 20 (Details are givens in current guidelines in Asia section.)
In 2017, a K-LUCAS Project, a 2-year multicenter lung cancer screening pilot project, was initiated to as evaluate the effectiveness and feasibility of lung cancer screening and validate new standards for the reporting form of LDCT and the quality of the screening by a web-based network system, and develop a risk prediction model for lung cancer. 74, 76 This project was sponsored by National Cancer Center and collaborated with Multidisciplinary Expert Committee. The LDCT screening was performed in high-risk smoker as a NLST criterion, (asymptomatic smokers aged 55−74 years with a smoking history ≥30 pack-years who had used tobacco within the last 15 years), 
Thailand
Triphuridet et al 80, 82 reported a high lung cancer detection rate (1.4%) of a prospective LDCT screening in endemic areas of tuberculosis (TB) started in 2012 among 634 heavy smokers aged 50-70 years without a history of active TB. Baseline lung cancer detection rate was 1.4% with 56% lung cancer being stage I. And the 1st-and 2ndyear incidence of lung cancer were 0.67% and 0.70%, respectively, and of active pulmonary TB were 0.50% and 0.52%, respectively. 81 From this cohort, the comparable diagnostic value on lung cancer detection of findings suspicious for lung cancer detected by LDCT and digital tomosynthesis (DT) was demonstrated (positive predictive value 34.8% vs 40%, respectively, with comparable sensitivity (80%) and specificity (98%)). 80 Saeteng et al. 83 reported an initial result of LDCT screening in the first relative of lung cancer patients, aged 20-65 years during January 2013 to May 2013. Nodules or other suspicious findings were classified as positive results. Nearly half of them (45.2%) had positive nodule with an average number and size of nodules was 2.1 nodules and 0.4 cm in diameter, respectively.
Summary of LDCT screening for lung cancer trials in Asia
The LDCT screening for lung cancer studies published in all languages before 21 February 2019 was identified by a literature search from the PubMed, Medline, Embase, and Scopus databases. There are 25 studies with published results in abstracts and manuscripts, 19 prospective cohorts, 5 retrospective cohorts, and 1 RCT study, with many differences between the studies such as study design, eligible subjects, screening regimens, and protocol for nodule management. Most of the study published data screened in asymptomatic adults, with annual follow-up, only one study had a 6-month interval 41 and three studies using 24-month interval. 53, 84, 85 The positive screening criteria varied from any pulmonary nodule including calcified nodule to only solid and part-solid nodule diameter 10 mm or larger. The studies were summarized and categorized according to the lung cancer risks, 16 had general participants,3 had with smoking history, 1 with family history of lung cancer, 4 with different lung cancer risks, and unknown risk factor (in Table 2 ).
Asymptomatic adults
There are 16 studies on LDCT screening in general subjects, 6 from Japan and 4 from China, 4 Korea, and 2 Taiwan, with baseline and overall lung cancer detection rates with range of 0.17-1.36% and 0.20-0.78%, respectively. The baseline and overall stage I lung cancers were 27.27-100% and 59.6-100%, respectively, with 75-95% 5-year lung cancer-specific survival rate. However, the low detection rates were observed more frequent in the early trials using LDCT with thicker slice protocol than the trials using the thinner slice. Moreover, in the trials with high lung cancer or stage 1 cancer detection rate, there were reported rates of AIS (formerly Bronchiolo-alveolar cell carcinoma (BAC)) as high as 40-70% of the total lung cancers diagnosed. 42, 67, 86, 87 The overall lung cancer detection rate and stage 1 lung cancer in the 6-month interval screening 11, 41 were 0.38% and 80.56%, respectively, while the corresponding rates in the annual studies 42, 43, 53, 54, 72, 73, 87, 89 were 0.21-0.78% and 60.87- 
Smokers
There are three prospective studies on annual LDCT screening in smokers from Israel, 78 Thailand, 81, 82 and Korea76 Two studies screened among heavy smoker with the history of tobacco smoking pack at least 30 pack-year aged 50-55 years or older 76, 81, 82 and one study screened among younger and lighter smoker as minimum aged of 40 years with 10 pack-year smoking history. 78 The baseline lung cancer detection rates ranged from 0.53% to 1.43% with 53.0-85.71% stage I lung cancer. As noted, the studies of heavy smokers reported the lower prevalence of lung cancer and stage 1 lung cancer using the higher baseline cutoff positive criteria were used for solid and PSN, and subsolid nodules were not defined as positive. 76, 81, 82 Different lung cancer risks Three Chinese 58, 85 and one Taiwanese 70,71 studies on the participant who had different lung cancer risks such as active and passive smoking history, lung cancer family history, history of kitchen fume or dust exposure, occupational exposure, and history of pulmonary TB or COPD. The studies demonstrated a wide range of baseline lung cancer detection rates ranging from 0.2% to 2.9%, the highest (2.9%) was observed in participants with indoor pollution, with 25-95% stage I lung cancer. Although the high overall lung cancer (2.3%) and early detection rate (95%) observed in the screening trial among neversmokers, 70, 71 the high frequency of invasive procedures, benign nodule underwent invasive procedure (false positive biopsy rate) and frequency of adenocarcinoma in situ (AIS) diagnosed also observed 3.16%, 26.14%, and 17.28%, respectively.
Family history of lung cancer and others
A prospective study on LDCT screening in participants with a family history of lung cancer from Taiwan 68 showed a high baseline lung cancer detection rates as 1.69% with 63% stage I lung cancer. However, 3.11% of study subjects underwent invasive procedures with 46% of them benign and 26% of lung cancer diagnosed as formerly BAC. An Indian study unknown lung cancer risk of participant showed an overall lung cancer detection rate 0.89% with 85% stage I lung cancer. The LDCT screening for lung cancer could yield high lung cancer and early-stage detection rates not only in the high-risk smoking and also never-smoker with other risk factors, and it seems also beneficial in countries with previously reported low and moderate lung cancer incidence and smoking prevalence as India, Thailand, and Israel. However, there were many factors that affect the lung cancer detection rate such as lung cancer risks of study participants, study protocol; LDCT slice thickness, screening interval, positive criteria, and nodule management. Identifying high risk and optimizing the study protocol and nodule management are important parts of effective LDCT screening.
Current guidelines in Asia
There are LDCT lung cancer screening guidelines published by profession societies from Japan, China, and Korea that are different based on their own national studies results reflecting different influences of medical subspecialties from each country. There are nodule management guidelines for lung cancer screening in Japan and China which are different in size and follow-up time of actionable nodules as summarized in Table 3 .
Japan
The Japanese "guidelines for the management of pulmonary nodules detected by low-dose CT" have been launched for 3 versions, at 2005, 2009, and 2013, respectively. 48 The key points of the third revision are 1) nodule size on screening CT image is obtained by calculating the average of the maximal diameter and the perpendicular diameter, 2) follow-up examinations for solid nodules depend on whether the patient is a smoker or nonsmoker, 3) lumped pure ground-glass nodules (GGNs) and mixed GGOs (or part-solid nodules) into a single category (after new international classification of adenocarcinoma of the lung in 2011) and proposed a decision tree based on the maximal diameter of the pulmonary nodule (≥15 mm or 5 mm), and 4) proposed a more detailed follow-up examination of pulmonary nodules that have been newly detected by repeat LDCT screening. The detail of the recommendation is summarized in Table 3 . The JSCTS have not introduced VDT measurements on a workstation or PET examinations into the decision tree in their guidelines as in Fleischner Society guidelines, the NELSON study, or the Danish Lung Cancer Screening Trial, because it is not easy to 
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perform VDT measurements on workstations or PET studies in ordinary clinical settings in Japan. 48 In 2013, the Japanese Imaging Guideline was published by the Japan Radiological Society and the Japanese College of Radiology. 19 The guideline recommended LDCT screening for lung cancer for persons aged 50 or over with a Brinkman index ≥600 (comparable with ≥30 pack-years of smoking) as grade C1, and the guidelines state that while scientific evidence is insufficient, LDCT screening may be considered as a measure for population-based screening. For the non-high-risk group, LDCT screening is not recommended as a means for population-based screening because of the lack of scientific evidence, grade C2. For individual screening, it may be performed after appropriate explanation about its unclear effects and disadvantages such as overdiagnosis and exposure.
China
The China national lung cancer screening guideline was developed in 2015 and was revised in 2018. 18, 58, 65 The guidelines recommended annual lung cancer screening with LDCT for high-risk individuals aged 50-74 years who have ≥20 pack-year smoking history and who currently smoke or have quit within the past 5 years.
Korea
In 2015, the Korean guideline for lung cancer screening was launched by a Korean multisociety collaborative committee. The guidelines recommended that the annual LDCT screening should be recommended to healthy subjects aged 55-74 years, current smokers, and ex-smokers (if less than 15 years have elapsed after smoking cessation) with ≥30 pack-years of smoking history, as the NLST criteria, with grade B quality of the evidence. 20 
Saudi Arabia
In 2018, a lung cancer prevention and screening guidelines were launched by a multidisciplinary team of experts in lung cancer representing different health care sectors and in coordination with the Saudi Lung Cancer Association of Saudi Thoracic Society. 91 The guidelines address the primary and secondary prevention approaches in lung cancer, including tobacco control and detection at earlier presentation. However, the team does not recommend that a national screening program be mandated or implemented for lung cancer at this stage until more data and studies provide stronger evidence to justify adopting a national program. 
Conclusion
Several countries in Asia have developed studies on LDCT lung cancer screening since 1990s and later since 2000s developed national lung cancer screening guidelines and nodule management protocol for their high-risk citizen (Figure 4 ). The screening studies enrolled various participants ranging from heavy smoker to never-smokers with other high-risk exposure and asymptomatic adults. The baseline lung cancer detection rates ranged from 0.2% to 2.9%, depending on risk characteristics of the participants. Higher rates (>1%) were observed in individuals with indoor air pollution exposure (RuraCSP -Xuanwei center, 2.9%), 8, 58 lung cancer family (1.7%), 68 and smokers (1.4%). 78, 81 Currently, there are several ongoing large-scale trials in Eastern Asia to evaluate the efficacy of LDCT screening for LCINS and light smokers (JECS, CHANCES, and TALENT) and risk score prediction model by using SNPs in never-smoker (TALENT), and to evaluate the feasibility of conducting population-based LDCT lung cancer screening (RuraCSP, CanSPUC, and K-LUCAS) and develop a web-based network system, and risk prediction model for lung cancer (CHANCES, and K-LUCAS).
LDCT screening in developing countries in Asia is challenging as high-risk individuals are at high risk due to tobacco smoking and environmental risk exposure, but there are insufficient resources and health care infrastructure. Additionally, there is no good strategy to screen for lung cancer in the never-smoking population who will develop lung cancer without any easily quantifiable risk factors. However, only the three highly developed countries, China, Japan, and South Korea, have published national-wide screening guidelines for lung cancer in heavy smokers. Many other countries have high lung cancer rates with a large population who still actively smoke, such as Turkey, Armenia, Georgia, Vietnam, and Philippines. There are no national lung cancer screening guidelines indicating the difficulty of finding resources to implement a large-scale endeavor that requires investment for equipment, technology, and skilled personals to detect a low incidence of lung cancer. For LDCT lung cancer screening to be successful and cost-effective, better screening strategies or biomarkers considering specific high-risk population for both smokers and nonsmokers, and carefully implemented in countries that have local factor as granulomatous disease prevalence, region by region or country by country need to be developed.
To implement lung cancer screening in Asia to maximize the screening benefit and minimize harms when there are insufficient resources and health care infrastructure, it is important to identify high-risk individuals by using simplified risk prediction model and/or affordable biomarkers, optimize screening regimens, and develop screening networks of local or primary care and screening centers which have multidisciplinary teams to provide additional management. However, tobacco control and smoking cessation policy remains the most important national priority for reducing the burden of lung cancer and other smoking-related diseases, together with raising awareness of smoking and environment risk.
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